Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 16/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 16/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190859 | 0.86 | SCN9A (0.56) | ALDH1A1LMNASCN9ARAB9AMAPT | |
| SCHEMBL4416032 | 0.78 | RAB9A (0.55) | ALDH1A1LMNASCN9ARAB9ASMN1; SMN2 | |
| SCHEMBL4983718 | 0.76 | KCNQ3 (0.43) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL4411279 | 0.76 | ALOX15 (0.43) | MEN1KMT2AALDH1A1LMNARAB9A | |
| SCHEMBL4429842 | 0.75 | KCNQ3 (0.43) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL4415178 | 0.74 | NPC1 (0.51) | MEN1KMT2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL3185799 | 0.71 | SCN9A (0.50) | ALDH1A1LMNABACE1SCN9ARAB9A | |
| SCHEMBL12182424 | 0.70 | ALDH1A1 (0.57) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL20552051 | 0.69 | PKM (0.42) | ALDH1A1LMNA | |
| SCHEMBL3452770 | 0.69 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061470-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | Neurogen Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008024433-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | PIGS, GPR174, GPR17 | KCNQ3 1378/4885KCNQ2 1399/4885KCNE1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.